Cargando…

Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection

Middle East respiratory syndrome coronavirus (MERS-CoV) is continuously spreading and causing severe and fatal acute respiratory disease in humans. Prophylactic and therapeutic strategies are therefore urgently needed to control MERS-CoV infection. Here, we generated a humanized monoclonal antibody...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qiu, Hongjie, Sun, Shihui, Xiao, He, Feng, Jiannan, Guo, Yan, Tai, Wanbo, Wang, Yufei, Du, Lanying, Zhao, Guangyu, Zhou, Yusen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Published by Elsevier B.V. 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109928/ https://www.ncbi.nlm.nih.gov/pubmed/27312105 http://dx.doi.org/10.1016/j.antiviral.2016.06.003

Ejemplares similares

A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV
por: Zhao, Guangyu, et al.
Publicado: (2018)

A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection
por: Tai, Wanbo, et al.
Publicado: (2016)

Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines
por: Du, Lanying, et al.
Publicado: (2016)

Enhanced Ability of Oligomeric Nanobodies Targeting MERS Coronavirus Receptor-Binding Domain
por: He, Lei, et al.
Publicado: (2019)

Vaccines for the prevention against the threat of MERS-CoV
por: Du, Lanying, et al.
Publicado: (2016)

Multi-Organ Damage in Human Dipeptidyl Peptidase 4 Transgenic Mice Infected with Middle East Respiratory Syndrome-Coronavirus
por: Zhao, Guangyu, et al.
Publicado: (2015)

Critical neutralizing fragment of Zika virus EDIII elicits cross-neutralization and protection against divergent Zika viruses
por: Tai, Wanbo, et al.
Publicado: (2018)

MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection
por: Tai, Wanbo, et al.
Publicado: (2023)

A novel human mAb (MERS-GD27) provides prophylactic and postexposure efficacy in MERS-CoV susceptible mice
por: Niu, Peihua, et al.
Publicado: (2018)

Blockade of the C5a–C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV
por: Jiang, Yuting, et al.
Publicado: (2018)

Advances in mRNA and other vaccines against MERS-CoV
por: Tai, Wanbo, et al.
Publicado: (2022)

Highly conserved M2e and hemagglutinin epitope-based recombinant proteins induce protection against influenza virus infection
por: Guo, Yan, et al.
Publicado: (2017)

The Potency of an Anti-MERS Coronavirus Subunit Vaccine Depends on a Unique Combinatorial Adjuvant Formulation
por: George, Parakkal Jovvian, et al.
Publicado: (2020)

A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV
por: Zhao, Guangyu, et al.
Publicado: (2013)

A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines
por: Du, Lanying, et al.
Publicado: (2013)

Correction: A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines
por: Du, Lanying, et al.
Publicado: (2022)

MERS-CoV infection causes brain damage in human DPP4-transgenic mice through complement-mediated inflammation
por: Jiang, Yuting, et al.
Publicado: (2021)

A Critical HA1 Neutralizing Domain of H5N1 Influenza in an Optimal Conformation Induces Strong Cross-Protection
por: Du, Lanying, et al.
Publicado: (2013)

Complement Receptor C5aR1 Inhibition Reduces Pyroptosis in hDPP4-Transgenic Mice Infected with MERS-CoV
por: Jiang, Yuting, et al.
Publicado: (2019)

Rational Design of Zika Virus Subunit Vaccine with Enhanced Efficacy
por: Tai, Wanbo, et al.
Publicado: (2019)

Human neutralizing mAbs against Middle East respiratory syndrome coronavirus (MERS-CoV)
Publicado: (2014)

Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines
por: Ma, Cuiqing, et al.
Publicado: (2014)

Effects of Adjuvants on the Immunogenicity and Efficacy of a Zika Virus Envelope Domain III Subunit Vaccine
por: Wang, Xinyi, et al.
Publicado: (2019)

Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection
por: Agrawal, Anurodh Shankar, et al.
Publicado: (2016)

Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain
por: Zhou, Yusen, et al.
Publicado: (2019)

Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus
por: Tang, Jian, et al.
Publicado: (2015)

Development of a safe and convenient neutralization assay for rapid screening of influenza HA-specific neutralizing monoclonal antibodies
por: Du, Lanying, et al.
Publicado: (2010)

Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2
por: Tai, Wanbo, et al.
Publicado: (2020)

An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses
por: Zhao, Guangyu, et al.
Publicado: (2010)

Structural basis for the neutralization of MERS-CoV by a human monoclonal antibody MERS-27
por: Yu, Xiaojuan, et al.
Publicado: (2015)

An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus
por: Zhao, Guangyu, et al.
Publicado: (2010)

Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity
por: Du, Lanying, et al.
Publicado: (2009)

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
por: Tai, Wanbo, et al.
Publicado: (2020)

Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model
por: Munster, Vincent J., et al.
Publicado: (2017)

Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses
por: Zeng, Lei-Ping, et al.
Publicado: (2017)

Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry
por: Wan, Yushun, et al.
Publicado: (2020)

Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread
por: Lu, Lu, et al.
Publicado: (2013)

Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III
por: Wu, Yanling, et al.
Publicado: (2017)

Synthetic vaccine affords full protection to mice against lethal challenge of influenza B virus of both genetic lineages
por: Gravel, Caroline, et al.
Publicado: (2021)

Development of a Humanized HLA-A2.1/DP4 Transgenic Mouse Model and the Use of This Model to Map HLA-DP4-Restricted Epitopes of HBV Envelope Protein
por: Ru, Zhitao, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_2v3g3en9ps1n97bi7oq6v5pmqo